Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 343

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

Open access
Insogna, Karl L, Briot, Karine, Imel, Erik A, Kamenický, Peter, Ruppe, Mary D, Portale, Anthony A, Weber, Thomas, Pitukcheewanont, Pisit, Cheong, Hae Il, Jan de Beur, Suzanne, Imanishi, Yasuo, Ito, Nobuaki, Lachmann, Robin H, Tanaka, Hiroyuki, Perwad, Farzana, Zhang, Lin, Chen, Chao-Yin, Theodore-Oklota, Christina, Mealiffe, Matt, San Martin, Javier, Carpenter, Thomas O, on behalf of the AXLES 1 Investigators · 2018 · Journal of Bone and Mineral Research

Abstract

In X-linked hypophosphatemia (XLH), inherited loss-of-function mutations in the PHEX gene cause excess circulating levels of fibroblast growth factor 23 (FGF23), leading to lifelong renal phosphate wasting and hypophosphatemia. Adults with XLH present with chronic musculoskeletal pain and stiffness, short stature, lower limb deformities, fractures, and pseudofractures due to osteomalacia, accelerated osteoarthritis, dental abscesses, and enthesopathy. Burosumab, a fully human monoclonal antibody, binds and inhibits FGF23 to correct hypophosphatemia. This report summarizes results from a double-blind, placebo-controlled, phase 3 trial of burosumab in symptomatic adults with XLH. Participants with hypophosphatemia and pain were assigned 1:1 to burosumab 1 mg/kg (n = 68) or placebo (n = 66) subcutaneously every 4 weeks (Q4W) and were comparable at baseline. Across midpoints of dosing intervals, 94.1% of burosumab-treated participants attained mean serum phosphate concentration above the lower limit of normal compared with 7.6% of those receiving placebo (p < 0.001). Burosumab significantly reduced the Western Ontario and the McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale compared with placebo (least squares [LS] mean ± standard error [SE] difference, –8.1 ± 3.24; p = 0.012). Reductions in WOMAC physical function subscale (–4.9 ± 2.48; p = 0.048) and Brief Pain Inventory worst pain (–0.5 ± 0.28; p = 0.092) did not achieve statistical significance after Hochberg multiplicity adjustment. At week 24, 43.1% (burosumab) and 7.7% (placebo) of baseline active fractures were fully healed; the odds of healed fracture in the burosumab group was 16.8-fold greater than that in the placebo group (p < 0.001). Biochemical markers of bone formation and resorption increased significantly from baseline with burosumab treatment compared with placebo. The safety profile of burosumab was similar to placebo. There were no treatment-related serious adverse events or meaningful changes from baseline in serum or urine calcium, intact parathyroid hormone, or nephrocalcinosis. These data support the conclusion that burosumab is a novel therapeutic addressing an important medical need in adults with XLH.© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jbmr.3475

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 343

Metadata

Authors
Insogna, K. L., Briot, K., Imel, E. A., Kamenický, P., Ruppe, M. D., Portale, A. A., Weber, T., Pitukcheewanont, P., Cheong, H. I., Jan de Beur, S., Imanishi, Y., Ito, N., Lachmann, R. H., Tanaka, H., Perwad, F., Zhang, L., Chen, C.-Y., Theodore-Oklota, C., Mealiffe, M., San Martin, J., Carpenter, T. O., & on behalf of the AXLES 1 Investigators
Venue
Journal of Bone and Mineral Research
Published
2018-06-26
Volume
33
Issue
8
Pages
1383-1393
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W2810290010
Cited by
343
References
21
FWCI
22.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. https://app.cochat.ai/papers/10.1002/jbmr.3475
The paper
Insogna, K. L., Briot, K., Imel, E. A., Kamenický, P., Ruppe, M. D., Portale, A. A., Weber, T., Pitukcheewanont, P., Cheong, H. I., Jan de Beur, S., Imanishi, Y., Ito, N., Lachmann, R. H., Tanaka, H., Perwad, F., Zhang, L., Chen, C.-Y., Theodore-Oklota, C., Mealiffe, M., . . . on behalf of the AXLES 1 Investigators. (2018). A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.3475

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.